Sign in

    IQVIA Holdings Inc (IQV)

    Q2 2024 Earnings Summary

    Reported on Jan 6, 2025 (Before Market Open)
    Pre-Earnings Price$239.86Open (Jul 22, 2024)
    Post-Earnings Price$239.86Open (Jul 22, 2024)
    Price Change
    $0.00(0.00%)

    What went well

    • IQVIA achieved strong bookings with a book-to-bill ratio of 1.27, representing the third highest bookings ever and is considered very strong by the company.
    • Mission-critical projects that were previously delayed are now proceeding, leading to an expected TAS growth of 6% to 7% in the second half of the year at constant currency.
    • The company is enhancing efficiency and margins through productivity programs, cost containment, and deployment of AI within operations to offset pricing pressures from clients.

    What went wrong

    • Pricing pressure from large pharma clients is increasing due to their multibillion-dollar cost-cutting programs, leading to tougher negotiations and potential margin compression. ,
    • 30% of the TAS business is "essentially flattish", requiring the remaining 70% to grow at high single digits to meet overall targets, highlighting uneven performance across business segments.
    • Despite raising revenue and EPS guidance, EBITDA guidance was slightly lowered due to unfavorable business mix, indicating potential profitability concerns.

    Q&A Summary

    1. EBITDA Guidance and Revenue Mix
      Q: Why lower EBITDA guidance despite higher revenue and EPS?
      A: Management explained that the tweaks in guidance are due to business mix changes affecting margins, but they are still delivering margin growth of about 30 basis points at the midpoint and 50 at the high end. The higher revenue is partly driven by slightly favorable FX.

    2. TAS Performance and Outlook
      Q: What's driving TAS improvement and expectations for second half?
      A: TAS is expected to grow 6% to 7% in the second half. The data business remains flat, but other segments, including real-world evidence, are picking up, with real-world growing in the high single to low teens. Delayed projects are now proceeding, contributing to the improvement.

    3. Pricing Pressure from Clients
      Q: How are pricing pressures affecting the business?
      A: Large pharma clients are implementing cost-cutting programs, leading to tougher price negotiations. Pricing continues to be challenging in both TAS and R&DS, but decision timelines are improving, giving confidence in forecasts.

    4. Bookings and Pipeline Growth
      Q: Are bookings and pipeline improving? Could book-to-bill accelerate?
      A: Bookings are strong with a book-to-bill ratio of 1.27x, the third highest ever. Qualified pipeline is up 12%, and RFP flows are up mid-teens percentage. Management is satisfied with current performance and doesn't anticipate a need for acceleration.

    5. Backlog Burn Rate and Conversion
      Q: What's the outlook for backlog burn rate and revenue conversion?
      A: Backlog burn rate remains around 7% to 7.1%, consistent with previous quarters. Next 12 months' revenue from backlog is $7.8 billion, up 6.9% from $7.3 billion last quarter, indicating confidence in revenue growth.

    6. Clinical Trial Cancellations
      Q: Are clinical trial cancellations improving?
      A: Cancellations have been slightly higher due to large pharma reprioritizing programs in response to the IRA. Average quarterly cancellations are around $500 million, within normal variability.

    7. M&A Activity and Capital Deployment
      Q: Can you discuss M&A contribution and future plans?
      A: Acquisitions have contributed about 1 point to growth this year. While they haven't spent as much as desired due to high valuations, they aim to spend more in the second half. Leverage ratio improved to 3.25x EBITDA, down from the high 4s.

    8. Winning Business from Top Clients
      Q: How did you win business from a top 5 client?
      A: The client preferred IQVIA's solution, which better aligned with their goals. Details of the program were not disclosed.

    9. EBP Funding and Revenue Mix
      Q: How will strong EBP funding affect revenue mix and services?
      A: Strong EBP funding is positive for mid- to long-term prospects but won't immediately change the revenue mix due to long cycles. Increased EBP work will lead to a higher mix of full-service projects over FSP in the future.

    10. Decision-Making Timelines
      Q: Are clients making decisions faster?
      A: Yes, decision-making timelines have improved broadly, not just for mission-critical projects. This contributes to more confident forecasts.

    Related Publications